Our versatile lentiviral delivery platform of ex vivo and in vivo technologies enables us to broaden our development pipeline beyond skin and connective tissue disorders to liver and metabolic diseases, as we continue to advance our lead clinical programs, and progress discovery and preclinical development of our early-stage novel product candidates.
Leveraging dual technology approach to expand development pipeline
Using ex vivo and in vivo technologies to develop novel therapies for genetic diseases